Apitherapy for Long Covid

A plain-English briefing on bee venom therapy (BVT) and the wider Apitherapy gifts-of-the-hive toolkit, with sections matched to specific long COVID symptoms. By Gillian Shelley with support from Claude.

Safety first

Bee venom is biologically active. That is precisely why it works, and also why it has to be handled carefully. Anyone considering BVT should be screened for bee allergy, start with a test sting (a single sting in a low-risk site) before any therapeutic protocol, and have an EpiPen on hand at every session. Roughly 1–7% of the general population has clinically significant bee venom allergy, and severe reactions can occur even in people who have been stung uneventfully in the past. With proper screening, slow dose escalation, and emergency preparedness, serious adverse events are uncommon in experienced practice.

In practical terms: I always do a test sting first, I carry epinephrine auto-injectors at every session, and I never escalate dose in someone whose body is signaling intolerance. The protocol below assumes that level of care.

What bee venom actually is:

Bee venom (apitoxin) from the is the complex secretion that a honey bee (Apis mellifera) injects when it stings. Bee venom is the stuff a honey bee shoots into you when it stings. About a dozen biologically active components do most of the therapeutic work, and four of them matter most for long COVID:

• 1.Melittin (40–60% of dry venom): small (injectable!) peptide made of 26 amino acids. It’s the dominant active component of bee venom and what makes bee stings hurt (which actually reduces overall nociception pain nerve firing!)

  • Pain english: acts as like a fire extinguisher calming down the body’s alarm system when it has been ringing incorrectly for too long. Can even fight viruses, including COVID.

  • Science speak: It’s strongly anti-inflammatory at low doses; suppresses NF-κB signaling and lowers TNF-α, IL-6, IL-8, and IFN-γ. Also has direct antiviral activity against enveloped viruses (a category that includes SARS-CoV-2).

• 2.Phospholipase A2 (10–12%): enzyme (a protein) made of about 128 amino acids and is the most abundant enzyme in bee venom

  • Plain english: helps train special "peacekeeper" regulatory T cells (Tregs) cells in your immune system so your body stops attacking itself by mistake.

  • Science speak: expands Foxp3+ regulatory T cells via dendritic-cell binding and the PGE2-EP2 pathway. Tregs are central to switching off chronic, dysregulated immune activation.

• 3.Apamin (2–3%): small peptide made of 18 amino acids.

  • Plain english: is the only part of bee venom small enough to cross the blood-brain-barrier (this is a really big deal!), where it helps calm overactive nerve cells. For people with long COVID, this may ease the brain fog, fatigue, and the body's trouble regulating things like heart rate and blood pressure (dysautonomia).

  • Science speak: the only venom component that crosses the blood-brain barrier; modulates SK potassium channels in neurons. Relevant to the cognitive-fatigue ('brain fog') and dysautonomia symptoms of long COVID.

• 4.Adolapin (~1%): small peptide made of about 103 amino acids and is an anti-inflammatory and pain-relieving compound.

  • Plain english: works like a natural pain and inflammation reliever. It blocks the same kinds of chemical signals that over-the-counter pain medicines target, so it can help quiet down the body-wide aches, soreness, and inflammation that often linger with long COVID.

  • Science speak: inhibits COX and lipoxygenase, blunting prostaglandin- and leukotriene-driven pain and inflammation.

What we now know about long COVID biology

Long COVID (post-acute sequelae of SARS-CoV-2 infection, PASC) is not one disease but a cluster of overlapping pathological processes. The pieces that are best supported by current evidence are:

• Persistent inflammation. Many long COVID patients show chronic elevation of IL-6, TNF-α, IFN-γ, and IL-8, the same cytokines that drive acute COVID severity, but at lower amplitude and for much longer.

• Immune dysregulation. Studies report low or exhausted Treg populations, persistent T-cell activation, and B-cell signatures resembling autoimmunity. The result is an immune system that is both over-active and improperly regulated.

• Possible viral persistence. SARS-CoV-2 RNA and spike protein have been detected in tissue reservoirs (gut, brain, lymph nodes) months after acute infection in some patients. This may continuously re-trigger the immune response.

• Microvascular and clotting abnormalities. Microclots and endothelial dysfunction reduce oxygen delivery to tissues, plausibly explaining exercise intolerance and 'post-exertional malaise.'

• Mast cell activation and dysautonomia. A subset of long COVID patients develop MCAS-like symptoms (flushing, GI upset, food sensitivity) and POTS-like autonomic dysfunction, both linked to inflammatory mediators acting on the nervous system.

How bee venom maps onto these mechanisms

Important to note: There is no large clinical trial of bee venom for long COVID specifically. That has to be said clearly up front. But the pharmacology is unusually well aligned with what is going wrong in long COVID, in a way that is hard to find for any single approved drug:

1. The cytokine profile is a direct match

Low-dose bee venom suppresses exactly the cytokines that are persistently elevated in long COVID: IL-6, IL-8, IFN-γ, and TNF-α. This is shown in cell-culture work, animal models, and human peripheral blood mononuclear cell studies. Anti-IL-6 biologics (tocilizumab) and anti-TNF agents are being trialed for long COVID for the same reason; bee venom hits these targets simultaneously and through a different mechanism.

2. Treg expansion addresses immune dysregulation

Bee venom phospholipase A2 reliably expands Foxp3+ regulatory T cells. Treg dysfunction is a recurring finding in long COVID immune profiling, and Treg-restoration strategies (low-dose IL-2 for example) are an active area of long COVID research. bvPLA2 is, in effect, a small-molecule Treg inducer.

3. Direct antiviral activity against SARS-CoV-2

If viral persistence is part of the picture, then a therapy with antiviral activity is mechanistically interesting. Melittin disrupts the lipid envelope of enveloped viruses, including coronaviruses. In vitro studies report virucidal activity against SARS-CoV-2 with EC50 values in the sub-microgram-per-mL range, with viral clearance starting at 12 hours and reaching maximum at 24 hours post-treatment. This is in vitro work, not clinical proof, but the mechanism (membrane disruption rather than receptor blocking) means it would not be defeated by spike-protein mutations the way monoclonal antibodies are.

4. Mast-cell modulation (paradoxical but real)

MCD peptide in venom triggers mast cell degranulation at high doses but appears to stabilize mast cell responses at low, repeated doses. This is the same desensitization principle that makes venom immunotherapy work for bee-allergic patients, and it is part of why MCAS-like symptoms can improve with sustained low-dose BVT.

5. Endogenous cortisol pulse

Each session triggers a brief, physiologic surge of the body's own cortisol. For people whose HPA axis has been blunted by chronic illness, this kind of pulsed challenge may help re-train normal cortisol rhythms, without the suppression that comes with continuous prescription steroids.

6. Apamin and the nervous-system symptoms

Apamin is the only bee venom peptide that crosses the blood-brain barrier. By modulating SK potassium channels in neurons, it influences excitability in circuits implicated in the fatigue, brain fog, and autonomic instability that dominate the long COVID experience. The clinical evidence here is preliminary, but the receptor-level rationale is real.

The evidence gap

As there are no published randomized controlled trials of bee venom therapy for long COVID, the evidence chain is: (1) we know the cytokine and immune dysregulation pattern of long COVID; (2) we have peer-reviewed evidence that bee venom and its isolated peptides act on those same targets; (3) we have in vitro evidence that melittin has antiviral activity against SARS-CoV-2; (4) we have anecdotal reports from Apitherapy practitioners of long COVID patients improving on BVT. Each link in that chain is real, but the chain as a whole is mechanistic plausibility plus clinical experience, not Randomized Control Trial proof.

By comparison, BVT for arthritis (especially knee OA) does have Randomized Control Trial -level evidence. The arthritis case is stronger; the long COVID case is more speculative but mechanistically tighter than most things being tried.

Long COVID in the wider PAIS picture

Long COVID is the newest and largest member of a clinical category that has been quietly recognized for decades: post-acute infection syndromes (PAIS). PAIS describes the persistent, multisystem illness that follows certain acute infections in a subset of patients, long after the initial pathogen has been cleared. The family includes:

• ME/CFS (myalgic encephalomyelitis / chronic fatigue syndrome): frequently triggered by Epstein-Barr virus, influenza, enterovirus, or other infections.

• Post-treatment Lyme disease syndrome (PTLDS): persistent fatigue, cognitive, and pain symptoms that continue after a documented course of antibiotics for Lyme.

• Post-SARS and post-MERS syndromes: well-documented in the original 2003 SARS and 2012 MERS cohorts; both produce a long-COVID-like picture lasting years.

• Post-Ebola, post-Q-fever, post-Giardia syndromes: each with their own published patient cohorts and overlapping symptom clusters.

• Long COVID (PASC): the newest entrant, but biologically the same kind of animal.

These conditions share a striking amount of underlying biology: persistent low-grade inflammation, dysregulated cytokine profiles (with the IL-6 / TNF-α / IFN-γ pattern recurring across the family), regulatory T cell deficits, mitochondrial and metabolic dysfunction, autonomic instability, and post-exertional malaise. The specific triggering pathogen seems to matter less than the dysregulated host response that follows it. This is why long COVID research is now informed by (and informs) research into the older PAIS conditions, and why interventions that act upstream of the specific pathogen tend to translate across the family.

The clinical relevance for BVT: a therapy that works on the dysregulated host response (Treg expansion, cytokine suppression, endogenous cortisol pulse, mast cell desensitization) is mechanistically pathogen-agnostic. If it helps post-Lyme, post-EBV, and post-SARS PAIS, the prior probability that it helps post-COVID PAIS is high, even before any long COVID-specific trial is run.

Bee venom's track record in PAIS-adjacent conditions

BVT does not have phase 3 trials in any PAIS condition. But it has decades of clinical and Apitherapy practitioner experience across this family, and the outcomes are encouraging in a way that is uncommon for chronic post-infectious illness:

• Multiple sclerosis. MS is increasingly understood as a near-universally post-EBV condition (Bjornevik 2022, Science), putting it firmly in PAIS-adjacent territory. Practitioner experience with earlier-stage and relapsing-remitting MS over long horizons has been more positive. The Treg-induction mechanism that helps RA is the same one that should, in principle, help MS, and the Apitherapy community has run informal protocols for MS for over thirty years.

• Chronic Lyme / PTLDS. This is where BVT has its strongest reputation in the PAIS world. Ellie Lobel's well-publicized recovery from late-stage neurological Lyme through accidental and then deliberate bee envenomation prompted a wave of clinical interest in the 2010s. Multiple Apitherapy practitioners have built protocols specifically for PTLDS, and the mechanism (membrane-disrupting peptides plus immune re-regulation) is plausible against the persistent Borrelia forms that some researchers believe drive PTLDS. The protocols used for long COVID are directly adapted from these Lyme protocols.

• ME/CFS. No formal trials. Apitherapy practitioners have nevertheless treated ME/CFS patients for decades. The pattern most often reported: cautious low-dose protocols are tolerable in patients who flare from almost everything else; cognitive symptoms and energy envelope tend to respond before peripheral pain does; and partial recovery, sometimes substantial, is described in practitioner case series. The same post-exertional malaise that limits exercise therapy in ME/CFS does not seem to be triggered by carefully-titrated BVT, possibly because the venom's effect is anti-inflammatory rather than oxidative.

• Fibromyalgia. Often co-morbid with the above conditions. Several small Korean Randomized Control Trials of bee venom acupuncture for fibromyalgia have reported clinically meaningful improvements in pain and fatigue, with effect sizes comparable to needle acupuncture and to standard NSAID protocols.

The argument that follows is not 'BVT has been proven for long COVID.' It hasn't. The argument is that long COVID is biologically the same kind of illness as several conditions in which BVT has decades of clinical experience and a real track record. The mechanism by which BVT appears to help those conditions (Treg expansion, cytokine suppression, endogenous cortisol pulsing, antiviral activity against enveloped viruses, mast-cell desensitization) is precisely the mechanism long COVID seems to need. For an off-label therapy in a new disease, that is an unusually strong inferential case.

Practical considerations for long COVID specifically

People with long COVID often have lower thresholds for inflammatory and autonomic 'flares,' which means starting low and going slow matters even more than in standard Apitherapy. A typical cautious protocol begins with a single test sting, then very gradual escalation (1 sting per session, then 2, then 3 over weeks), watching closely for post-exertional malaise patterns. Sting placement is usually along the spine and at acupuncture points associated with immune and nervous-system regulation.

Hydration, electrolytes, and rest on treatment days reduce flare risk. People on antihistamines, mast-cell stabilizers (cromolyn, ketotifen), or low-dose naltrexone can usually continue these alongside BVT. Strong immunosuppressants (high-dose steroids, biologics) may blunt the Treg-mediated benefit and warrant timing discussion with the prescribing physician.

The wider Apitherapy Gifts-of-the-Hive Toolkit for long COVID

Bee venom is the flagship of the Apitherapy approach, but it isn't the whole story. The beehive is essentially a small pharmacy, and several of the other 'hive medicines' have pharmacology that maps directly onto specific facets of long COVID. The protocols I use combine BVT with several of these, matched to which symptoms are most prominent in the individual person. Each one is summarized below with its mechanism, the symptoms it most usefully addresses, and the evidence currently available.

Many of these can also be used on non-sting days as part of the recovery rhythm. See the section on between-session support at the end of this briefing.

Propolis: the antiviral and immune modulator

Propolis is the resinous substance bees collect from plant buds and use to seal and sterilize the hive. Pharmacologically it is the most concentrated source of plant flavonoids and phenolic acids in the Apitherapy toolkit, and arguably the strongest antiviral hive medicine.

Mechanism: the star compound is CAPE (caffeic acid phenethyl ester), which inhibits NF-κB, the same master inflammatory pathway that bee venom melittin targets, but reached through completely different chemistry. Propolis flavonoids (galangin, pinocembrin, chrysin) and phenolic acids (caffeic, ferulic) have demonstrated direct antiviral activity against enveloped viruses including SARS-CoV-2; multiple in silico and in vitro studies show propolis compounds inhibiting the SARS-CoV-2 main protease (Mpro).

Most relevant long COVID symptoms: persistent fatigue with active inflammation; reactivation of latent viruses (EBV, HSV, VZV), a recurring pattern in long COVID; chronic sinus or respiratory issues; gut inflammation. If suspected viral persistence is part of the picture, propolis is the hive medicine to pair with BVT.

Evidence: Silveira et al. 2021 (Biomedicine & Pharmacotherapy) ran a Brazilian Randomized Control Trials in hospitalized COVID-19 patients and found that adjunctive Brazilian green propolis significantly reduced length of hospital stay and reduced rates of acute kidney injury. Multiple in vitro studies have also documented SARS-CoV-2 inhibition (Berretta et al. 2020).

How to use: tincture (Brazilian green or Russian propolis are the most studied), 15–30 drops 1–3× daily, or capsules. Look for verified flavonoid content. Holds up well to long-term daily use; the main caution is that pure-resin allergies exist and a small skin or oral test is wise on first use.

Honey: the daily metabolic foundation

Honey is the concentrated, enzymatically transformed nectar bees produce as winter food. Beyond the sore-throat reputation, raw honey is genuinely pharmacologically active.

Mechanism: a slow, sustained release of hydrogen peroxide gives broad antimicrobial action; polyphenols are antioxidant and mildly anti-inflammatory; methylglyoxal (the active in manuka) adds direct antibacterial activity. Raw honey supports the gut microbiome through its prebiotic oligosaccharides.

Most relevant long COVID symptoms: gut dysbiosis (an underappreciated piece of long COVID, with the gut now recognized as a likely SARS-CoV-2 reservoir); oxidative stress; lingering post-infectious cough or sore throat; low-grade systemic inflammation; the energy dips between meals that come from blood-sugar dysregulation in PAIS.

Evidence: Ashraf et al. 2023 (Phytotherapy Research) ran a multi-center Randomized Control Trial in COVID-19 patients and found that honey plus Nigella sativa significantly shortened SARS-CoV-2 viral clearance time and symptom duration. Older trials show benefit for upper-respiratory infection generally.

How to use: 1–2 tablespoons of raw, unfiltered honey daily. Choose manuka with MGO 250+ for active immune support, or local raw honey for general use and pollen-allergy desensitization. Avoid heating; the enzymes are heat-labile.

Bee pollen: the mitochondrial multivitamin

Bee pollen is the male fertilizing dust of flowers, gathered by foraging bees and bound with a small amount of nectar and salivary enzymes into pellets. Nutritionally it is one of the densest natural foods on the planet.

Mechanism: contains all essential amino acids; B-complex vitamins; the flavonoids rutin and quercetin; and trace minerals including zinc and selenium. Quercetin in particular has documented mitochondrial-protective and mast-cell-stabilizing effects, and is being used directly in several long COVID research protocols.

Most relevant long COVID symptoms: deep fatigue; exercise intolerance; post-exertional malaise; slow recovery from physical activity; cognitive endurance; the general 'depleted battery' picture. Essentially the energy-system support layer.

Evidence: human trials of pollen specifically are limited; quercetin has emerging evidence in long COVID; centuries of use in European folk medicine for convalescence.

How to use: start with ¼ teaspoon of fresh, refrigerated, raw pollen daily. Pollen allergy is real, and a careful introduction matters. Build up over weeks to 1–2 teaspoons. Best chewed (saliva starts breaking down the pollen wall) or mixed into yogurt, smoothies, or honey.

Bee bread (perga): the bioavailable upgrade

Bee bread is pollen that has been packed into honeycomb cells, mixed with nectar and bee saliva, and lacto-fermented in the hive over weeks. Often called the natural probiotic of the hive.

Mechanism: fermentation by hive lactobacilli breaks down the tough sporopollenin pollen wall, multiplying nutrient bioavailability several-fold over raw pollen. Adds beneficial lactic acid bacteria. Lower allergic potential than raw pollen because the fermentation breaks down some of the allergenic proteins.

Most relevant long COVID symptoms: same energy and mitochondrial support as pollen, but better-tolerated and more bioavailable in patients with the GI dysfunction that often accompanies long COVID. Particularly useful when standard pollen feels too heavy to digest, or when the gut microbiome needs rebuilding.

Evidence: limited Western research; widely used in Eastern European Apitherapy practice for chronic illness recovery.

How to use: a small daily amount (½ to 1 teaspoon) on the tongue or mixed into food. Bitter and tangy from the fermentation; texture and taste matter more than dose.

Royal jelly: the neurotrophic one

Royal jelly is the secretion fed exclusively to queen bees, and to all bee larvae for the first three days of life. It is the nutrient that turns a generic worker larva into a queen, and it contains the most biologically distinctive compound in the entire hive.

Mechanism: the unique fatty acid 10-HDA (10-hydroxy-2-decenoic acid, found nowhere else in nature) has demonstrated neurotrophic effects in animal models, specifically increasing brain-derived neurotrophic factor (BDNF) and supporting hippocampal function. Royal jelly also has effects on the HPA axis and modulates estrogen signaling, which matters because long COVID frequently disrupts both.

Most relevant long COVID symptoms: brain fog; cognitive dysfunction; memory issues; mood changes; hormonal disruption (low testosterone in men, menstrual changes in women, thyroid suppression). This is the hive medicine for the neurological and endocrine layer of long COVID.

Evidence: animal studies on neuroprotection and cognitive enhancement (Hashimoto et al. 2005); small human studies on cognitive function in elderly populations; mechanistic work on 10-HDA and BDNF induction.

How to use: ½ teaspoon of fresh-frozen royal jelly daily, taken sublingually for best absorption. Freeze-dried capsules are a distant second. Quality matters enormously. Much commercial royal jelly is heat-damaged and effectively inert. Source from beekeepers who handle it cold.

Apilarnil: the post-viral recovery tonic

Apilarnil is an extract of three- to seven-day-old male drone larvae, traditional in Romanian Apitherapy and lesser-known in the US. Pharmacologically it is one of the most interesting and underused hive medicines.

Mechanism: contains naturally occurring testosterone precursors and other steroid hormones; complete amino acid profile; peptides; enzymes; growth factors. Functions as an adaptogen and an anabolic recovery support, the closest natural analog to a 'rebuilding' tonic in the Apitherapy toolkit.

Most relevant long COVID symptoms: post-illness depletion; HPA axis exhaustion; documented post-COVID low testosterone (now well-described in men); loss of muscle mass; prolonged convalescence; reduced libido and stamina. The 'I'm just empty and not rebuilding' symptom cluster.

Evidence: largely Romanian and Eastern European clinical experience; small studies on hormonal effects and recovery; not extensively studied in Western trials. The clinical reputation in its home region is strong despite the thin published literature.

How to use: tincture or freeze-dried preparation, daily. Sourcing is the limiting factor in the US; find a Romanian-tradition Apitherapy supplier. Quality varies considerably.

Hive air (apiair): the respiratory recovery piece

Hive air is the inhalation therapy of air drawn directly from inside an active beehive. A specialized box or apparatus filters out the bees while channeling the hive's volatile-rich air to the patient through a mask. Practiced widely in Slovenia, Romania, Germany, and increasingly in the US.

Mechanism: hive air contains a complex mixture of volatile organic compounds (propolis aerosols, beeswax volatiles, and plant terpenes from the resins the bees collect) that are anti-inflammatory, antimicrobial, and mucolytic when inhaled. Effectively a continuous, low-dose inhaled propolis treatment.

Most relevant long COVID symptoms: persistent shortness of breath; post-COVID lung scarring or chronic cough; reduced exercise capacity due to respiratory limits; sinus inflammation; asthma-like symptoms that emerged or worsened after COVID; loss of smell that hasn't recovered. This is the hive medicine for the respiratory and lung-recovery layer of long COVID.

Evidence: practitioner experience from Slovenian, Romanian, and German Apitherapy clinics; a long track record for asthma and COPD that has translated naturally to post-COVID care. A few European academic groups are now studying hive air specifically for long COVID respiratory recovery; published trials are still pending.

How to use: requires either visiting an Apitherapy practitioner with a hive-air apparatus or building your own setup if you keep bees. Sessions of 15–30 minutes, 2–3× weekly during active treatment phases.

Symptom-matched starting points

For people who want a quick map of which combinations of hive medicines pair best with BVT for which long COVID phenotype:

• Persistent fatigue with active inflammation: BVT + propolis + bee pollen.

• Brain fog and cognitive dysfunction: BVT + royal jelly + propolis.

• Respiratory symptoms (shortness of breath, cough, lung recovery): BVT + hive air + propolis.

• Gut dysfunction and dysbiosis: BVT + raw honey + bee bread.

• Hormonal/HPA exhaustion and post-illness depletion: BVT + apilarnil + royal jelly.

• Suspected viral persistence (EBV reactivation, lingering SARS-CoV-2 reservoir): BVT + propolis + raw manuka honey.

• Mast cell activation symptoms (flushing, food sensitivities, skin reactions): BVT (slow titration) + raw honey + bee pollen for quercetin.

Between-session support and detox

Bee venom triggers a real inflammatory clearance load, and people with long COVID, whose detox pathways are often already burdened, benefit substantially from active support on non-sting days. The standard rhythm:

• Hydration plus electrolytes: non-negotiable. Dehydration is the fastest route to feeling awful after a session.

• Liver support: milk thistle, dandelion root tea, lemon water, bitters before meals. Castor oil packs over the liver are old-school but effective.

• Lymphatic movement: dry brushing, gentle rebounding, walking, manual lymphatic drainage if available. Lymph is where much of the post-sting clearance actually happens.

• Binders, used carefully: activated charcoal, chlorella, or zeolite can help with inflammatory-mediator overflow. Take well away from food and supplements (2+ hours) or they bind nutrients too. Long COVID patients with MCAS-like symptoms benefit most.

• Epsom salt baths: magnesium plus mild sweating. Both help.

• Protected rest the day after a session: most clearance and tissue repair happens during this window. Don't schedule demands.

• Anti-inflammatory food day: bone broth, leafy greens, berries, no sugar, no alcohol. The other hive medicines (raw honey, bee pollen, propolis) layer in here naturally.

For long COVID specifically: do not underestimate the dose response on sting days. People with a tight post-exertional envelope often do better with shorter recovery cycles between very small sessions than with larger sessions followed by long detox crashes.

The honest summary

Long COVID is a disease of chronic inflammation, immune dysregulation, and possibly viral persistence, and it is the newest member of a recognized family of post-acute infection syndromes (PAIS) that includes ME/CFS, post-Lyme syndrome, post-SARS, post-MERS, and others. Bee venom hits each of the implicated pathways: it suppresses the exact cytokines that are elevated; it expands the regulatory T cells that are missing; and it has in vitro antiviral activity against SARS-CoV-2 itself. There are no long COVID-specific clinical trials yet, but BVT does have decades of practitioner experience in the older PAIS conditions, with encouraging anecdotal and small-trial results in MS, post-Lyme, ME/CFS, and fibromyalgia.

Around the venom, the wider Apitherapy toolkit fills in the symptom-specific gaps: propolis for the antiviral and inflammatory layer, royal jelly for cognition and brain fog, bee pollen and bee bread for the energy and mitochondrial system, raw honey for the gut, apilarnil for post-illness depletion, and hive air for the respiratory recovery piece. Used together and matched to the dominant symptom pattern, these become a coherent Apitherapy approach to long COVID rather than a single intervention.

For a condition with no FDA-approved treatments, a system whose pharmacology lines up this well with the underlying biology, and which has a real track record in adjacent diseases of the same family, is a reasonable thing to consider, especially when delivered with proper screening, slow escalation, and emergency preparedness.

References

Kasozi KI, Niedbała G, Alqarni M, Zirintunda G, Ssempijja F, Musinguzi SP, et al. (2020). Bee Venom — A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections. Frontiers in Public Health 8:594458. https://www.frontiersin.org/articles/10.3389/fpubh.2020.594458/full

Al Naggar Y, Giesy JP, Abdel-Daim MM, Javed Ansari M, Al-Kahtani SN, Yahya G. (2021). Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic? Saudi Journal of Biological Sciences 28(3):1519–1527. https://www.sciencedirect.com/science/article/pii/S1319562X20306951

Memariani H, Memariani M, Robati RM, Nasiri S, Abdollahimajd F, Baseri Z. (2023). Bee Venom and Its Two Main Components — Melittin and Phospholipase A2 — As Promising Antiviral Drug Candidates. Pathogens 12(11):1325. https://pmc.ncbi.nlm.nih.gov/articles/PMC10674158/

Mustafa MB, Ali HG, Eldeen AKM, Wahbi A, Sayed AS, El-Kahky DM. (2023). Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection. Future Journal of Pharmaceutical Sciences 9:96. https://pmc.ncbi.nlm.nih.gov/articles/PMC10630947/

Mustafa MB, Wang YT, Ji ZL. (2022). Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection. Scientific Reports 12:3434. https://www.nature.com/articles/s41598-022-07341-x

Park S, Baek H, Jung KH, Lee G, Lee H, Kang G-H, Lee G, Bae H. (2021). Bee venom phospholipase A2 alleviates collagen-induced polyarthritis by inducing Foxp3+ regulatory T cell polarization in mice. Scientific Reports 11:3463. https://www.nature.com/articles/s41598-021-82298-x

Park S, Erdogan S, Hwang D, Hwang S, Han EH, Lim Y-H. (2020). Bee Venom Phospholipase A2 Induces Regulatory T Cell Populations by Suppressing Apoptotic Signaling Pathway. Toxins 12(4):198. https://pmc.ncbi.nlm.nih.gov/articles/PMC7150970/

Wehbe R, Frangieh J, Rima M, El Obeid D, Sabatier J-M, Fajloun Z. (2019). Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules 24(16):2997. https://www.mdpi.com/1420-3049/24/16/2997

Carpena M, Nuñez-Estevez B, Soria-Lopez A, Simal-Gandara J. (2024). The current landscape of the antimicrobial peptide melittin and its therapeutic potential. Frontiers in Immunology 15:1326033. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1326033/full

Pucca MB, Cerni FA, Oliveira IS, Jenkins TP, Argemí L, Sørensen CV, et al. (2019). Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy. Frontiers in Immunology 10:2090. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02090/full

Davis HE, McCorkell L, Vogel JM, Topol EJ. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology 21:133–146. https://www.nature.com/articles/s41579-022-00846-2

Choutka J, Jansari V, Hornig M, Iwasaki A. (2022). Unexplained post-acute infection syndromes. Nature Medicine 28:911–923. https://www.nature.com/articles/s41591-022-01810-6

Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, et al. (2005). A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology 65(11):1764–1768. https://pubmed.ncbi.nlm.nih.gov/16221950/

Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. (2022). Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375(6578):296–301. https://www.science.org/doi/10.1126/science.abj8222

Silveira MAD, De Jong D, Berretta AA, Galvão EBS, Ribeiro JC, Cerqueira-Silva T, et al. (2021). Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial. Biomedicine & Pharmacotherapy 138:111526. https://www.sciencedirect.com/science/article/pii/S0753332221002092

Berretta AA, Silveira MAD, Cóndor Capcha JM, De Jong D. (2020). Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease. Biomedicine & Pharmacotherapy 131:110622. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430291/

Ashraf S, Ashraf S, Ashraf M, Imran MA, Choudhary BA, Hussain G, et al. (2023). Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial. Phytotherapy Research 37(2):627–644. https://onlinelibrary.wiley.com/doi/10.1002/ptr.7640

Hashimoto M, Kanda M, Ikeno K, Hayashi Y, Nakamura T, Ogawa Y, et al. (2005). Oral administration of royal jelly facilitates mRNA expression of glial cell line-derived neurotrophic factor and neurofilament H in the hippocampus of the adult mouse brain. Bioscience, Biotechnology, and Biochemistry 69(4):800–805. https://pubmed.ncbi.nlm.nih.gov/15849420/

Pasupuleti VR, Sammugam L, Ramesh N, Gan SH. (2017). Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits. Oxidative Medicine and Cellular Longevity 2017:1259510. https://www.hindawi.com/journals/omcl/2017/1259510/